About the company
Headquartered in San Antonio, Texas, bioAffinity Technologies Inc is a groundbreaking biotechnology company at the forefront of noninvasive diagnosis and targeted treatment of early-stage cancer and lung diseases. The company's primary focus revolves around the development of proprietary diagnostic tests and cancer therapeutics, incorporating state-of-the-art technology specifically designed to zero in on cancer cells and populations that indicate a diseased state. Driven by a mission to revolutionize healthcare, bioAffinity Technologies Inc is determined to create innovative and accurate methods for detecting and monitoring various diseases, including lung diseases and different types of cancers. By harnessing the power of cutting-edge technologies, the company aims to enhance the early detection and treatment of these life-threatening conditions. The cornerstone of bioAffinity's approach lies in their noninvasive diagnostic tests, which have the potential to significantly improve patient outcomes and reduce healthcare costs. Leveraging their expertise in molecular imaging and biomarker analysis, the company aims to pioneer revolutionary techniques that identify and quantify diseases with unparalleled precision. These tests have the capacity to detect the presence of malignancies or lung diseases at the earliest stages, allowing for timely interventions and dramatically improving patient survival rates. Moreover, bioAffinity Technologies Inc is committed to developing targeted cancer therapeutics, using their innovative technology to selectively attack cancer cells while minimizing harm to healthy tissues. This personalized treatment approach has the potential to revolutionize the field of oncology by tailoring therapies to each patient's specific molecular profile. By precisely targeting cancer cells, bioAffinity's therapies aim to increase efficacy while reducing side effects commonly associated with traditional treatments, such as chemotherapy and radiation. The groundbreaking work conducted by bioAffinity Technologies Inc presents a promising future in the battle against cancer and lung diseases. The company continues to work diligently to refine and develop their technologies, with the ultimate goal of transforming the concept of healthcare. By creating noninvasive diagnostic tests that detect diseases in their earliest stages and developing targeted therapies that are both effective and safe, bioAffinity is pioneering a new era of precision medicine. As the demand for early-stage diagnostic tools and innovative cancer treatments continues to grow, bioAffinity Technologies Inc is dedicated to staying at the forefront of scientific advancements. Their ongoing research and development efforts hold the promise of improving patient care and outcomes, ultimately leading to a world where cancer and lung diseases are detected early and effectively treated, saving countless lives.
Website: https://bioaffinitytech.com
Data updated: June 2, 2026
